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DENDRITIC CELL ROLE IN THE IMMUNE
SYSTEM AND ITS MANIPULATION
The immune system works to contain
infections through activation of different
molecules and cell types. Correct presenta-
tion of antigens by antigen-presenting cells
(APCs) is a critical step necessary to ini-
tiate an immune response. APCs have the
ability to take-up and process antigens, and
express high levels of co-stimulatory and
major histocompatibility complex (MHC)
molecules bound to antigens (1).
Dendritic cells (DCs) are innate
immune cells first characterized and
reported by Ralph Steinman in 1973 (2).
For their unique properties and features,
DCs are the most important APCs act-
ing at the interface of innate and adaptive
immunity, which results in the activation
of immune responses in the body. Distinct
subsets of DCs are associated with lineage
and receptor expression patterns (3).
Dendritic cells have different roles in
the immune system, such as activation and
regulation of adaptive immune responses,
and other opposing functions in the induc-
tion of tolerance and anergy (4). During
immune responses, DCs are crucial deci-
sion makers toward the development of
naïve T cells to T helper type 1 (Th1) or
type (Th2) profile (5).
Among the different families of mole-
cules expressed by DC to aid in their func-
tion, one of them is the family of toll-like
receptors (TLR). TLR which are expressed
by different types of DCs, and bind to com-
mon molecules associated with pathogens.
Once bound, molecules such as bacter-
ial lipopolysaccharide and hypomethylated
CpG DNA, can induce activation of bio-
chemical cell pathways, resulting in over-
expression of MHC, co-stimulatory mole-
cules (CD80, CD86), and cytokines (6).
In this context, a number of methods
have been available to manipulate DCs
from diverse sites in the body resulting in
activated cells for therapy. These methods
include reinfusion of unloaded DCs; rein-
fusion of DCs co-cultured with peptides or
proteins of interest; in vivo DC loading; DC
transfection with antigen-encoding viruses
or nucleic acids; and DC-derived exosomes
(7, 8). After this, DCs might be ready
to promote protection or treat specific
diseases.
In this context, the availability of meth-
ods to manipulate DCs in laboratory, arise
as an important tool for immunointerven-
tions in different diseases. In this opinion
article, we focused on the basis of DC
approaches already available in the field
of cancer currently in test for infectious
diseases, and future interventions that are
needed.
DENDRITIC CELL APPROACHES FOR
CANCER
Since initial tests with murine models, acti-
vated DCs have been an attractive alterna-
tive to treat cancer as an immunostimu-
latory vaccine. This vaccine has the abil-
ity to induce effective cancer immunity by
inducing Th1 cells and specific cytotoxic T
lymphocytes to tumor antigens, as well as
natural killer (NK) cells (9, 10). The poten-
tial of anti-cancer vaccines also lies on their
capacity to stimulate long-lasting memory
T cells against tumor antigens. Among the
subsets of memory T cells, the presence
of central memory (Tcm) cells has been
associated with a better antitumor function
than effector memory cells (11).
The first attempt of vaccination was per-
formed with DCs derived from patients
with non-Hodgkin’s lymphoma who have
failed current treatment. Immunoglobulin
idiotype from the patient’s tumor were
used to load DCs ex vivo and then were
reinjected into the patient’s body – what
resulted in the complete remission of the
tumor (12).
To date, many clinical assays employ-
ing different methods to activate DCs have
been in test for different types of cancers.
Most trials were performed using autolo-
gous DCs pulsed ex vivo with tumor anti-
gens or derived peptides, and administered
to patients with or without chemother-
apy or other immune agent (13). However,
other types of interventions are in course
in clinical trials, such as those using DCs
engineered to express tumor antigens with
or without molecules such as CD40 lig-
and, CD70, and TLR-4 (14, 15). Impor-
tant results were shown in one trial per-
formed by Tel et al. (16), who reported
a strong immune-specific response against
melanoma after administration of a par-
ticular subset of DCs, called plasmacytoid-
DCs (pDCs) pulsed with melanoma spe-
cific antigens. pDCs have been seen as
interesting players in this task, since once
properly activated they are able to produce
high levels of gamma-interferon (IFN-γ)
and elicit a robust Th1 immune response.
Most clinical assays have used ex
vivo manipulation of patient’s peripheral
blood monocytes cultured in the pres-
ence of interleukin (IL)-4 and recombinant
granulocyte macrophage-colony stimulat-
ing factor (GM-CSF) to achieve DCs for
therapy (17). In this way, a DC-based
preparation of autologous cells expanded
ex vivo in the presence of a prostatic
acid phosphatase/GM-CSF fusion protein
(sipuleucel-T, Provenge®) was approved
by the US FDA and other interna-
tional regulatory agencies for use in
patients with advanced metastatic prostate
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cancer (18). From trials initiated in 2012,
sipuleucel-T is involved in at least seven
trials against prostate cancer, combin-
ing sipuleucel-T with: different regimens
of radiotherapy (19); administration of
monoclonal antibody against cytotoxic T
lymphocyte-associated protein 4 (CTLA-
4) (20); administration of recombinant
human IL-7 (21); and injection of DNA-
based anti-cancer vaccine together with
GM-CSF (22). Thus, it is expected that
further results with sipuleucel-T will be
disclosed in the next years.
However, ex vivo manipulation of DCs
are limited by some factors, such as the
high cost, the long time needed to handled
in laboratory, and ultimately the high risk
of infection to the patients (23, 24). The
latter issue is clearly one of the most impor-
tant, since cancer patients might be already
immunocompromised and susceptible to
diverse pathogen infections.
To overcome this issue, searching for
new alternatives to ex vivo manipulation
are in course, and many of them are being
developed, such as activation and load-
ing DCs with antigens in vivo. One good
example is the use of specific peptides com-
bined with GM-CSF to attract and acti-
vate DCs in vivo, which showed prospective
clinical results (25). Other strategy is the
use of cancer cells genetically modified to
express GM-CSF, resulting in the attrac-
tion and activation of DCs (26). Another
tactic is the delivery of oncolytic viruses,
which preferentially infect and kill cancer
cells (27).
One of the most promising approaches
is the in vivo targeting of specific DC recep-
tors using antibodies coupled with antigens
(28, 29). It was verified that administration
of this type of vaccine with DC activators
such as TLR3, TLR-7-8, and CD40 agonists
allows the establishment of immunity in
diverse diseases settings, including infec-
tions [e.g., malaria and human immunod-
eficiency virus (HIV)] and cancer (30, 31).
Although prospective results are dis-
closed and expected, most clinical trials fail
to go beyond Phase II due to a reduced suc-
cess rate. This indicates that more studies
are needed to fill gaps in the comprehen-
sion of the immune response necessary to
eliminate cancer and explore this knowl-
edge in DC cancer vaccines, such as the use
of TLR agonists and the particular role of
each DC subset. In parallel, work groups
are dedicating efforts to identify better cor-
relates of clinical efficacy to evaluate results
from clinical trials more properly.
DENDRITIC CELL APPROACHES FOR
INFECTIOUS DISEASES
Dendritic cell manipulation offers an inter-
esting approach to fight against infectious
diseases, and an alternative to prompt
a protective immunity, since some treat-
ments are ineffective or inexistent in those
(32, 33). Previous studies have shown that
DCs can induce protection against differ-
ent pathogens, including protozoan, bac-
teria, and virus. DCs recognize microor-
ganisms through TLR or C-type lectin
receptors (34, 35). Vaccination works have
reported protection against leishmaniasis
(36, 37), Herpes simplex virus (38, 39),
influenza virus (40), and Candida albi-
cans (41), among other pathogens, such
as HIV.
Human immunodeficiency virus has
different mechanisms of evasion from the
immune system, and nowadays the main
source of treatment to infected patients is
to follow combination antiretroviral ther-
apy (cART) for life. However, attention
was drawn to promising results obtained
by the use of DC-based vaccine against
HIV. Lu et al. (42) performed the first
success clinical trial described, and found
a significant reduction in plasma viral
load (VL) after administration of autolo-
gous DCs loaded with inactivated autol-
ogous virus in HIV-1 infected patients.
At least 12 studies have achieved interest-
ing results, and evolved to clinical trials
with HIV-1 infected patients and reported
HIV-1 specific-immunological responses
(43). Recently, García et al. (44) observed
a significant decrease in VL in HIV-
1 chronic infected patients who have
interrupted cART treated with autologous
monocyte-derived DCs pulsed with autol-
ogous heat-inactivated whole HIV. Pre-
viously, García et al. (45) also showed
promising results with significant drop in
VL in HIV-1 infected patients off-cART
treated with the same vaccine prepara-
tion. Based on this, it is expected that in
the next few years good results will be
achieved, enhancing the chances to develop
an immunointervention that could help
infected individuals.
Although now it is possible to tar-
get vaccine antigens to DCs in T and
B areas and to modulate their function
with adjuvants, there is still no currently
approved DC therapy for infectious dis-
eases, and most experimental approaches
are especially with animal models (46).
One good example is leishmaniasis, which
is one of the most important neglected
diseases that cause deaths and morbid-
ity in more than 88 countries. Current
human anti-leishmania vaccines available
are limited by their inefficiency to con-
fer protection against the different species
and also by their safety, which is con-
tested. DCs approaches for leishmania-
sis were proposed by different groups of
research with remarkable results showing
low levels of parasite burden and high lev-
els of Th1 cytokines in animals treated
(47, 48). However, results from studies
with animal models might be difficult to
translate the results to humans, and it
will remain a goal for further investiga-
tions. DCs therapy for leishmaniasis and
other infectious diseases would aid mainly
refractory patients to current treatments
due to high toxic drugs that are available
for use or the increasing number of resis-
tant pathogens. Furthermore, immuno-
compromised individuals, such as those
with AIDS or grafted, would be benefited
by more safety and effective treatments
against different pathogens.
CONCLUSION
In the last couple of years, DC therapies
approaches have been shown to be feasi-
ble and secure. Successful results were and
are being obtained with cancer patients
and animal models. DCs have an extra-
ordinary capacity to orchestrate the host’s
immune response, which offers new per-
spectives for the development of vaccines
and immunotherapeutic strategies against
cancer and infectious diseases among oth-
ers. However, due to the success that is been
observed with cancer and also due to the
efforts that is being put by many research
groups in the development of antigens and
adjuvants with good immunological stim-
ulatory capacities, we believe that in a closer
future DC therapies will be also a viable
approach to treat and/or prevent infectious
diseases.
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